The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Paul Bourgine receives Vinnova Emerging Technology Grant for the OssiGel technology

Paul Bourgine, pre-clinical WCMM fellow

Vinnova is a Swedish innovation agency, dedicated to fund Swedish innovation and fostering sustainable growth. Their commitment lies in propelling Sweden as a dynamic force in the realm of innovation within the context of a sustainable world. Paul Bourgine and his group will receive 970 000 SEK from November 2023 to June 2024 for the proposed development of the OssiGel technology, which aims to test the formation of human mini-bones as personalized drug-testing platforms.

Paul Bourgine and his group members proposed to validate the OssiGel technology in the context of Acute Myeloid Leukemia (AML). The aim was to generate personalized human ossicles from AML patients cells and test whether the patient ossicles will reflect leukemia development which is occurring in their bones. Next, they planned to validate the human ossicles as an advanced in vivo drug-testing platform, where Paul proposes to demonstrate the possibility of assessing patient-drug responses with standard-of-care treatments.

At the end of the planned project, OssiGel is expected to be validated as a superior personalized platform to predict patient's drug responses, which will lay the foundation for the development of a commercial product through the creation of a start-up company. The creation of a start-up company will start attracting venture funding and in 2024, we Paul and his team will initiate the distribution and validation of the OssiGel product to collaborators such as local academic groups and companies. Following initial distribution locally, Paul and his team expects to distribute the product more broadly in Sweden and Denmark, where an industrial partner could be identified for global production and distribution of OssiGel.